FDA approves IntraBio's Aqneursa for rare ataxia-telangiectasia disorder

FDA has granted approval for Aqneursa, a therapy developed by privately held biotech IntraBio, to treat ataxia-telangiectasia, a rare genetic disorder. The decision expands treatment options for patients with this condition.

Aqneursa targets the underlying disease mechanisms and was evaluated in clinical studies that demonstrated its safety and efficacy, leading to the agency’s favorable review. The approval marks IntraBio’s first product to reach the market.

In related news, Alkermes disclosed new data from its ADHD program, though details of the results were not included in the brief. The company’s update adds to the broader landscape of neuroscience developments.